TroVax

BIOLOGICAL6 trials

Sponsors

Oxford BioMedica, Cancer Research UK, The Methodist Hospital Research Institute

Conditions

Carcinoma, Renal CellClear Cell Renal CarcinomaColorectal NeoplasmsHormone Refractory Prostate CancerProstatic Neoplasms

Phase 2

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

CompletedNCT00083941

Oxford BioMedicaCarcinoma, Renal Cell

Start: 2004-08-31End: 2008-07-31Updated: 2020-10-19

Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed

CompletedNCT00259844

Cancer Research UKColorectal Neoplasms

Start: 2004-06-30End: 2006-12-31Target: 20Updated: 2006-07-18

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

CompletedNCT00325507

Oxford BioMedicaCarcinoma, Renal Cell

Start: 2005-11-30End: 2008-07-31Updated: 2020-10-19

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

CompletedNCT00448409

The Methodist Hospital Research InstituteProstatic Neoplasms

Start: 2006-05-31End: 2007-05-31Updated: 2016-03-17

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

TerminatedNCT01194960

Oxford BioMedicaHormone Refractory Prostate Cancer

Start: 2010-08-31End: 2013-03-31Updated: 2020-10-19

Phase 3

TroVax Renal Immunotherapy Survival Trial

CompletedNCT00397345

Oxford BioMedicaClear Cell Renal Carcinoma

Start: 2006-09-30End: 2009-12-31Updated: 2020-10-19